| 1 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031068)
|
| 2 |
Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
|
| 3 |
Clinical pipeline report, company report or official report of Novartis.
|
| 4 |
International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011
|
| 5 |
Clinical pipeline report, company report or official report of Xencor.
|
| 6 |
ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
|
| 7 |
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64.
|
| 8 |
Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4.
|
| 9 |
Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95.
|
| 10 |
IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5.
|
| 11 |
Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
|
|
|
|
|
|
|
